This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
Similar Posts
M14 General Principles on Planning, Designing, Analyzing, and Reporting of Non-interventional Studies That Utilize Real-World Data for Safety Assessment of Medicines
M14 General Principles on Planning, Designing, Analyzing, and Reporting of Non-interventional Studies That Utilize Real-World Data for Safety Assessment of MedicinesBlendHouse Allerton LLC. Allerton, PA. 483 issued 02/20/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 02/20/2025
Short Title (70 char) BlendHouse Allerton LLC. Allerton, PA. 483 issued 02/20/2025
FEI Number 1921383
Firm Name BlendHouse Allerton LLC
Record Type 483
State PA
Establishment Type ManufacturerField Science – Laboratory Manual
The Laboratory Manual is a reference manual for FDA personnel. It provides FDA personnel with information on internal procedures to be used as an agency policy for testing consumer products, training of laboratory staff, report writing, safety, research, review of private laboratory reports and courCelestaPro – 718613 – 11/03/2025
Unapproved New Drugs/Misbranded BotoxWhat’s New Related to Drugs
Want to know what’s new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.MJS Medicals – 11/03/2025
Unapproved New Drugs/Misbranded/Botox